
Success achieved with the first-in-class oral anti-cancer drug, Inobrodib, by CellCentric and Sygnature Discovery.
An integrated project team at Sygnature Discovery worked collaboratively to design, synthesise, and support the pre-clinical development of Inobrodib, a new, first-in-class oral anti-cancer drug